Shares of Exactech Inc. (NASDAQ:EXAC) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $27.99 and last traded at $27.99, with a volume of 12,760 shares trading hands. The stock had previously closed at $27.29.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Exactech from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a report on Wednesday. Robert W. Baird upgraded Exactech from a “neutral” rating to an “outperform” rating and upped their target price for the company from $21.00 to $26.00 in a report on Wednesday, April 13th.

The firm has a market capitalization of $399.09 million and a price-to-earnings ratio of 25.48. The firm has a 50-day moving average price of $26.87 and a 200-day moving average price of $22.53.

Exactech (NASDAQ:EXAC) last posted its quarterly earnings results on Monday, August 1st. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.30 by $0.01. During the same period in the prior year, the business earned $0.26 earnings per share. The business earned $66.10 million during the quarter, compared to analyst estimates of $64.18 million. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, equities analysts predict that Exactech Inc. will post $1.18 earnings per share for the current year.

In other news, CFO Joel C. Phillips sold 3,900 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $23.13, for a total value of $90,207.00. Following the completion of the sale, the chief financial officer now directly owns 100,632 shares of the company’s stock, valued at approximately $2,327,618.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gary J. Miller sold 9,664 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The shares were sold at an average price of $24.37, for a total value of $235,511.68. Following the completion of the sale, the executive vice president now directly owns 30,914 shares of the company’s stock, valued at $753,374.18. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Exactech stock. Morgan Stanley raised its stake in shares of Exactech Inc. (NASDAQ:EXAC) by 6.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 67,495 shares of the company’s stock after buying an additional 3,982 shares during the period. Morgan Stanley owned 0.48% of Exactech worth $1,225,000 as of its most recent filing with the SEC.

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes surgical instruments, bone cement and other implant product lines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.